Maternal Cardiovascular Disease in the Respiratory Syncytial Virus Prevention Era: A Systematic Review of Vaccine Safety, Nirsevimab Strategies, and Timing–prematurity Trade-offs
Letters in Medical Sciences · 2026
DOI: 10.4103/lms.lms_28_25 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Letters in Medical Sciences, 2026. Verfasst von Wiku Andonotopo und 19 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
Maternal cardiovascular disease (CVD) is an increasingly important challenge in perinatal care, particularly as new strategies to prevent respiratory syncytial virus (RSV) in early infancy move into routine practice. This systematic review examines the safety, timing, and clinical integration of maternal RSV vaccination and neonatal nirsevimab administration in pregnancies complicated by CVD. A comprehensive search of PubMed, PMC, Scopus, Embase, and ClinicalTrials.gov was conducted through May 2025 following PRISMA 2020 guidance. Of 1254 records identified, 31 met the inclusion criteria after independent screening and full-text assessment by two reviewers, with risk-of-bias evaluation performed using the revised Cochrane risk of bias tool for randomized trials, risk of bias in nonrandomized studies of interventions, and the A Measurement Tool to Assess Systematic Reviews, version two tools. Across studies, maternal RSV vaccination was consistently well tolerated in individuals with compensated cardiac function, and vaccination during 30–32 weeks’ gestation produced the most favorable balance between maternal hemodynamic stability and efficient antibody transfer. In contrast, women with decompensated heart failure, persistent peripartum cardiomyopathy, or advanced pulmonary hypertension were better served by neonatal protection with nirsevimab, avoiding potential cardiovascular stress in late gestation. No concerning trends in hypertensive, thrombotic, or arrhythmic events were identified following vaccination. Implementation reports highlighted persistent inequities in access and supply, with low-resource settings facing the greatest barriers to timely maternal immunization and monoclonal rollout. Together, the evidence supports a tailored “cardiac–immune precision” approach that aligns preventive strategy with maternal cardiovascular status and local health-system capacity. This synthesis underscores the need for coordinated surveillance, equitable program design, and multidisciplinary decision-making to optimize maternal and neonatal outcomes.
Zitieren
APA
Andonotopo, W., Lukas, E., Pramono, M. B. A., Dewantiningrum, J., Prabowo, W., Bachnas, M. A., Sanjaya, I. N. H., Wiradnyana, A. A. G. P., Kusuma, A. A. N. J., Gumilar, K. E., Darmawan, E., Akbar, M. I. A., Aldiansyah, D., Suryawan, A., Putra, R. A., Anwar, A. D., Nugraha, L. A. K., Andanaputra, W. E. K., Dharma, W. A. K., & Stanojevic, M. (2026). Maternal Cardiovascular Disease in the Respiratory Syncytial Virus Prevention Era: A Systematic Review of Vaccine Safety, Nirsevimab Strategies, and Timing–prematurity Trade-offs. Letters in Medical Sciences. https://doi.org/10.4103/lms.lms_28_25
Vancouver
Andonotopo W, Lukas E, Pramono MBA, Dewantiningrum J, Prabowo W, Bachnas MA, et al. Maternal Cardiovascular Disease in the Respiratory Syncytial Virus Prevention Era: A Systematic Review of Vaccine Safety, Nirsevimab Strategies, and Timing–prematurity Trade-offs. Letters in Medical Sciences. 2026. doi:10.4103/lms.lms_28_25
BibTeX
@article{Andonotopo2026,
author = {Andonotopo, Wiku and Lukas, Efendi and Pramono, Mochammad Besari Adi and Dewantiningrum, Julian and Prabowo, Wisnu and Bachnas, Muhammad Adrianes and Sanjaya, I Nyoman Hariyasa and Wiradnyana, Anak Agung Gede Putra and Kusuma, Anak Agung Ngurah Jaya and Gumilar, Khanisyah Erza and Darmawan, Ernawati and Akbar, Muhammad Ilham Aldika and Aldiansyah, Dudy and Suryawan, Aloysius and Putra, Ridwan Abdullah and Anwar, Anita Deborah and Nugraha, Laksmana Adi Krista and Andanaputra, Waskita Ekamaheswara Kasumba and Dharma, Wibisana Andika Krista and Stanojevic, Milan},
title = {Maternal Cardiovascular Disease in the Respiratory Syncytial Virus Prevention Era: A Systematic Review of Vaccine Safety, Nirsevimab Strategies, and Timing–prematurity Trade-offs},
journal = {Letters in Medical Sciences},
year = {2026},
doi = {10.4103/lms.lms_28_25}
}
EUVIMED